Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PBM Quality Comparisons Feature In Senate Dems’ Medicare Rx Bill

Executive Summary

PBMs delivering a drug benefit under Medicare would be subject to quality and consumer satisfaction comparisons under Sen. Bob Graham's (D-Fla.) Medicare Rx bill

You may also be interested in...



Senate “Tripartisan” Medicare Rx Drug Bill To Have 50% Copay, $35 Premium

The Medicare prescription drug bill under development by a five-member "tripartisan" coalition within the Senate Finance Committee includes a 50% copay and a $35 monthly premium

Senate “Tripartisan” Medicare Rx Drug Bill To Have 50% Copay, $35 Premium

The Medicare prescription drug bill under development by a five-member "tripartisan" coalition within the Senate Finance Committee includes a 50% copay and a $35 monthly premium

House Medicare Rx Bill Fits “Fundamental” PBM Model, Express Scripts Says

The House Republican Medicare Rx proposal would fit with Express Scripts' "fundamental" pharmacy benefit management model, the company reminded analysts during a June 18 investor day

Related Content

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel